Sulfate ion

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Sulfate ion
Accession Number
DB14546
Type
Small Molecule
Groups
Experimental, Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • Sulfate
  • Sulfate dianion
  • Sulfate(2-)
  • Sulfuric acid ion(2-)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
RurinaSulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)LiquidTopicalNano Bio Tech Co.,Ltd2017-07-01Not applicableUs
RurinaSulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)LiquidTopicalTELOM-X GENE Co., Ltd.2017-07-01Not applicableUs
Telom-X-geneSulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)LiquidTopicalTELOM-X GENE Co., Ltd.2017-07-01Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
RurinaSulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)LiquidTopicalNano Bio Tech Co.,Ltd2017-07-01Not applicableUs
RurinaSulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)LiquidTopicalTELOM-X GENE Co., Ltd.2017-07-01Not applicableUs
Telom-X-geneSulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)LiquidTopicalTELOM-X GENE Co., Ltd.2017-07-01Not applicableUs
Categories
UNII
7IS9N8KPMG
CAS number
14808-79-8
Weight
Average: 96.063
Monoisotopic: 95.951729178
Chemical Formula
O4S
InChI Key
QAOWNCQODCNURD-UHFFFAOYSA-L
InChI
InChI=1S/H2O4S/c1-5(2,3)4/h(H2,1,2,3,4)/p-2
IUPAC Name
sulfate
SMILES
[O-]S([O-])(=O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0001448
ChemSpider
1085
BindingDB
26992
ChEBI
16189
HET
SO4
Wikipedia
Sulfate
PDB Entries
101m / 102m / 103m / 104m / 105m / 106m / 107m / 108m / 109m / 110m
show 18721 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentChildhood Solid Neoplasm / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Neuroblastoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1RecruitingSupportive CareHuman Immunodeficiency Virus 1 Positive / Kaposi's Sarcoma AIDS Related1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Untreated Adult Acute Myeloid Leukemia1
1RecruitingTreatmentDiffuse Large B-Cell Lymphoma Activated B-Cell Type / Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type / Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements / High Grade B-Cell Lymphoma, Not Otherwise Specified / Lymphoma, Large B-Cell, Diffuse (DLBCL) / T-Cell/Histiocyte-Rich Large B-Cell Lymphoma1
1, 2Active Not RecruitingTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Plasmablastic Lymphoma / AIDS-Related Primary Effusion Lymphoma / Ann Arbor Stage I Diffuse Large B-Cell Lymphoma / Ann Arbor Stage I Grade 3 Follicular Lymphoma / Ann Arbor Stage II Diffuse Large B-Cell Lymphoma / Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Ann Arbor Stage III Diffuse Large B-Cell Lymphoma / Ann Arbor Stage III Grade 3 Follicular Lymphoma / Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma / Ann Arbor Stage IV Grade 3 Follicular Lymphoma / CD20 Positive / Grade 3b Follicular Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Plasmablastic Lymphoma / Primary Effusion Lymphomas / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Diffuse Large B-Cell Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Grade 3 Follicular Lymphoma1
1, 2Active Not RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Stage II Angioimmunoblastic T-cell Lymphoma / Stage II Enteropathy-Associated T-Cell Lymphoma / Stage III Angioimmunoblastic T-cell Lymphoma / Stage III Enteropathy-Associated T-Cell Lymphoma / Stage IV Angioimmunoblastic T-cell Lymphoma / Stage IV Enteropathy-Associated T-Cell Lymphoma1
1, 2Active Not RecruitingTreatmentAnn Arbor Stage II Non-Hodgkin Lymphoma / Ann Arbor Stage III Non-Hodgkin Lymphoma / Ann Arbor Stage IV Non-Hodgkin Lymphoma / Stage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative / Leukemias / Untreated Adult Acute Lymphoblastic Leukemia1
1, 2RecruitingTreatmentAggressive Non-Hodgkin Lymphoma / B-cell Non-Hodgkin's Lymphomas / CD20 Positive / Diffuse Large B-Cell Lymphoma Unclassifiable / Intravascular Large B-Cell Lymphoma / Primary Mediastinal (Thymic) Large B-cell Lymphoma / T-Cell/Histiocyte-Rich Large B-Cell Lymphoma / Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult Acute Lymphoblastic Leukemia in Complete Remission / Burkitt's Lymphoma / CD20 Positive / Childhood Acute Lymphoblastic Leukemia in Complete Remission / Leukemias / Lymphoma, Lymphoblastic1
2Active Not RecruitingTreatmentBlastoid Variant Mantle Cell Lymphoma / CD20 Positive / Malignant Lymphomas / Mantle Cell Lymphoma (MCL) / Pleomorphic Variant Mantle Cell Lymphoma1
2Active Not RecruitingTreatmentDesmoplastic/Nodular Medulloblastoma / Medulloblastoma With Extensive Nodularity / Medulloblastomas / Nevoid Basal Cell Carcinoma Syndrome / Untreated Childhood Medulloblastoma1
2Not Yet RecruitingTreatmentAggressive Non-Hodgkin Lymphoma / Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma / Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma / Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma / Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements / High Grade B-Cell Lymphoma, Not Otherwise Specified / Indolent Non-Hodgkin's Lymphomas / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma / Transformed Non-Hodgkin Lymphoma1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult Acute Lymphoblastic Leukemia in Complete Remission / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Leukemias / Philadelphia Chromosome Positive / Untreated Adult Acute Lymphoblastic Leukemia1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias / Lymphoma, Lymphoblastic / T Acute Lymphoblastic Leukemia / T Lymphoblastic Lymphoma1
2RecruitingTreatmentBladder Adenocarcinoma / Bladder Mixed Adenocarcinoma / Bladder Squamous Cell Carcinoma / Bladder Urothelial Carcinoma / Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant / Infiltrating Bladder Urothelial Carcinoma With Giant Cells / Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation / Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation / Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant / Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant / Infiltrating Bladder Urothelial Carcinoma, Nested Variant / Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant1
2RecruitingTreatmentMedulloblastomas / Untreated Childhood Medulloblastoma1
3Active Not RecruitingTreatmentAdult Supratentorial Primitive Neuroectodermal Tumor (PNET) / Childhood Supratentorial Primitive Neuroectodermal Tumor / Ewing Sarcoma of Bone / Extraosseous Ewing Sarcoma / Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Non-Metastatic Extraskeletal Ewing Sarcoma / Peripheral Primitive Neuroectodermal Tumor of Bone / Peripheral Primitive Neuroectodermal Tumor of Soft Tissues / Peripheral Primitive Neuroectodermal Tumor of the Kidney / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
3Active Not RecruitingTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor1
3Active Not RecruitingTreatmentExtraocular Retinoblastoma1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Undifferentiated Leukemia (AUL) / Childhood T Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Not Yet RecruitingTreatmentB Acute Lymphoblastic Leukemia / B Lymphoblastic Lymphoma / Blasts More Than 25 Percent of Bone Marrow Nucleated Cells / Down Syndrome (DS)1
3Not Yet RecruitingTreatmentLow Grade Glioma (LGG) / Neurofibromatosis Type 1 / Visual Pathway Glioma1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentChildhood Ganglioneuroblastoma / Childhood Neuroblastoma / INRG Stage L2 / INRG Stage M / INRG Stage MS / NMYC Gene Amplification / Recurrent Neuroblastoma1
3SuspendedTreatmentAnaplastic Medulloblastoma / Medulloblastomas / Untreated Childhood Medulloblastoma / Untreated Childhood Pineoblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
4CompletedDiagnosticCathartic Colon1
Not AvailableWithdrawnNot AvailableAcute Lymphoblastic Leukaemias (ALL) / Leukemias / Untreated Childhood Acute Lymphoblastic Leukemia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidTopical
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-0.84ChemAxon
pKa (Strongest Acidic)-3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area80.26 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity11.53 m3·mol-1ChemAxon
Polarizability5.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Classification
Not classified

Drug created on July 12, 2018 15:40 / Updated on May 01, 2019 12:01